Shining more light on RAS inhibition during the COVID-19 pandemic

The coronavirus disease 2019 (COVID-19) pandemic has resulted in unprecedented challenges throughout the nephrology community. Notably, it was quickly realized that the virus responsible for COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), uses the angiotensin-converting